NDA 220106 is the FDA application for LISRAYA (brepocitinib tosylate). The FDA's Orange Book lists the applicant of record as PRIOVANT THERAPEUTICS INC and the first approval on it as Aug 27, 2026. Code name used in development: PF-06700841. Owner today: Roivant Sciences Ltd. (Nasdaq: ROIV).
Page updated Nov 19, 2026. FDA records: Drugs@FDA NDA 220106 · Orange Book NDA 220106
| Brand name (FDA) | LISRAYA Orange Book trade name: LISRAYA |
|---|---|
| Active ingredient (FDA) | BREPOCITINIB TOSYLATE |
| Code name | PF-06700841 Source: Pfizer clinical study report synopsis, May 20, 2021 “Investigational Product: Brepocitinib (PF-06700841)” |
| FDA applicant of record | PRIOVANT THERAPEUTICS INC FDA Orange Book data files as of Nov 13, 2026 |
|---|---|
| Owner today | Roivant Sciences Ltd. (ROIV) Source: Roivant Sciences press release (8-K exhibit 99.1), Aug 27, 2026 “Roivant (Nasdaq: ROIV) today announced that the U.S. Food and Drug Administration (FDA) has approved” |
| Earlier / partner | Pfizer: holds a minority stake in the FDA applicant Source: Roivant Sciences investor presentation (8-K exhibit 99.1), Aug 28, 2026 “ROIV owns 71%1 of Priovant, with Pfizer owning 24%.” … “As of June 30, 2026. 65% on a fully diluted basis.” |
| No. | Trade name | Form; route | Strength | Approved |
|---|---|---|---|---|
| 001 | LISRAYA | TABLET;ORAL | EQ 30MG BASE | Aug 27, 2026 |
Drug page: /drug/brepocitinib
Orange Book data: FDA Orange Book data files, as of Nov 13, 2026. Approval dates are the FDA's dates for each product; a later supplement (a new use) does not change them.